Erratum: Oxymatrine Inhibits development of morphine-induced tolerance associated with decreased expression of P-glycoprotein in rats (Integrative Cancer Therapies (2010) 9:2 (213-218) DOI: 10.1177/1534735410369671);Oxymatrine inhibits development of morphine-induced tolerance associated with decreased expression of p-glycoprotein in rats

Integrative Cancer Therapies

Volumn 9, Issue 2, 2010, Pages 213-218

  Li, Yanwei ^a   Yue, Hui ^b   Xing, Yanmin ^b   Sun, Haiyan ^b   Pan, Zhanyu ^b   Xie, Guangru ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b KEY LABORATORY OF CANCER PREVENTION AND THERAPY   (China)

Author keywords

morphine; oxymatrine; P gp; Sophora japonica; tolerance

Indexed keywords

ADENOSINE TRIPHOSPHATE; GLYCOPROTEIN P; MEMANTINE; MORPHINE; MORPHINE SULFATE; OXYMATRINE; ALKALOID; MULTIDRUG RESISTANCE PROTEIN; NARCOTIC ANALGESIC AGENT; QUINOLIZINE DERIVATIVE;

ADJUVANT THERAPY; ANALGESIA; ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESEARCH; DRUG TOLERANCE; FAR WESTERN BLOTTING; LATENT PERIOD; MALE; MORPHINE TOLERANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; RAT; TAIL FLICK TEST; TREATMENT DURATION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; PAIN; WISTAR RAT;

ALKALOIDS; ANALGESICS, OPIOID; ANIMALS; BLOTTING, WESTERN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG TOLERANCE; GENE EXPRESSION REGULATION; MALE; MORPHINE; P-GLYCOPROTEIN; PAIN; QUINOLIZINES; RATS; RATS, WISTAR;

EID: 77954183919     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735411413636     Document Type: Erratum

References (25)

1. World Health Organization. Cancer Pain Relief: With a Guide to Opioid Availability. 2 nd ed. Geneva, Switzerland: World Health Organization; 1996.
2. Payne R. Role of epidural and intrathecal narcotics and peptides in the management of cancer pain. Med Clin North Am. 1987; 71: 313-327.
3. Winters WD, Hance AJ, Cadd GG, Quam DD, Benthuysen JL Ketamine-and morphine-induced analgesia and catalepsy: tolerance, cross-tolerance, potentiation, residual morphine levels and naloxone action in the rat. J Pharmacol Exp Ther. 1988; 244: 51-57.
4. Hassan HE, Mercer SL, Cunningham CW, Coopa A., Eddingtona ND Evaluation of the P-glycoprotein (Abcb1) affinity status of a series of morphine analogs: comparative study with meperidine analogs to identify opioids with minimal P-glycoprotein interactions. Int J Pharm. 2009; 375: 48-54.
5. Hamabe W., Maeda T., Fukazawa Y., et al. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav. 2006; 85: 629-636.
6. Aquilante CL, Letrent SP, Pollack GM, Brouwer KLR. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 2000; 66: 47-51.
7. Dagenais C., Graff CL, Pollack GM Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem Pharmacol. 2004; 67: 269-276.
8. Letrent SP, Pollack GM, Brouwer KR, Brouwer KLR. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos. 1999; 27: 827-834.
9. Peng XQ, Zhang WH, Li J. Reversal of multidrug resistance in K562/A02 cells by oxymatrine [in Chinese]. Chin J Clin Oncol. 2008; 35: 1127-1129.
10. Zhou JJ, Jiang YX, Jin SJ, Tao LJ, Liu LJ Studies on analgesic effects and sites of oxymatrine-carbenoxolone sodium complex [in Chinese]. Zhongguo Zhong Yao Za Zhi. 2008; 33: 822-824.
11. Ho JW, Ngan Hon PL, Chim WO Effects of oxymatrine from Ku Shen on cancer cells. Anticancer Agents Med Chem. 2009; 9: 823-826.
12. Luk JM, Wang X., Liu P. Traditional Chinese herbal medicines for treatment of liver fibrosis and cancer: from laboratory discovery to clinical evaluation. Liver Int. 2007; 27: 879-890.
13. Engi H., Hohmann J., Gang G., et al. Chemoprevention and inhibition of P-glycoprotein in cancer cells by Chinese medicinal herbs. Phytother Res. 2008; 22: 1671-1676.
14. Klepstad P., Dale O., Skorpen F., Borchgrevink PC, Kaasa S. Genetic variability and clinical efficacy of morphine. Acta Anaesthesiol Scand. 2005; 49: 902-908.
15. Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett. 2006; 234: 4-33.
16. Tanabe M., Ieiri I., Nagata N., et al. Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J Pharmacol Exp Ther. 2001; 297: 1137-1143.
17. He L., Liu GQ Interaction of multidrug resistance reversal agents with P-glycoprotein ATPase activity on blood-brain barrier. Acta Pharmacol Sin. 2002; 23: 423-429.
18. Garrigos M., Mir LM, Orlowski S. Competitive and non-competitive inhibition of the multidrug-resistance-associated P-glycoprotein ATPase: further experimental evidence for a multisite model. Eur J Biochem. 1997; 244: 664-673.
19. Marchetti S., Mazzanti R., Beijnen JH, Schellens JH Concise review: clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein). Oncologist. 2007; 12: 927-941.
20. Corbett AD, Henderson G., McKnight AT, Paterson SJ 75 years of opioid research: the exciting but vain quest for the Holy Grail. Br J Pharmacol. 2006; 147 (suppl 1). S153-S162.
21. Blendy JA, Maldonado R. Genetic analysis of drug addiction: the role of cAMP response element binding protein. J Mol Med. 1998; 76: 104-110.
22. Stefano GB, Bianchi E., Guarna M., et al. Nicotine, alcohol and cocaine coupling to reward processes via endogenous morphine signaling: the dopamine-morphine hypothesis. Med Sci Monit. 2007; 13: RA91-RA102.
23. Wakako H., Maeda T., Kiguchi N., Yamamoto C., Tokuyama S., Kishioka S. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J Pharmacol Sci. 2007; 105: 353-360.
24. Ge CY, Qin GQ, Liu JJ, et al. Treatment observation of compound matrine injection as an adjuvant for cancerous pain in advanced cancer patients. Chin J Curr Clin Med. 2009; 7: 23-26.
25. Kamei J., Xiao P., Ohsawa M., et al. Antinociceptive effects of (+)-matrine in mice. Eur J Pharmacol. 1997; 337: 223-226.